-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 2, 2021, Shanghai Lechun Biotechnology Co.
, Ltd.
(hereinafter referred to as Lechun Biotechnology) and the world-renowned membrane manufacturer RENOLIT SE (hereinafter referred to as: Renolit) signed a strategic cooperation in Fengxian Lingang Industrial Park, Shanghai Agreement
.
With the rapid development of biopharmaceuticals and the urgent demand for the supply of films in single-use systems, Renault decided to further invest in the construction of its local factory in China
.
And this strategic cooperation with Lechun Biotechnology is also aimed at building a single-use system film supply channel, aiming to provide localized production capacity, improve the long-term stability of the supply chain, and look forward to providing better domestic biotechnology companies The service supports the rapid, healthy and stable development of China Biopharmaceuticals
With the support of Renault's global innovation experts, the Chinese team is currently committed to establishing the infrastructure, striving to launch the first batch of trial production within this year
.
Zhang Wenfang, general manager of Renault Medical and Health Beijing Division, said: Thank you very much Lechun Bio for choosing Renault as a partner
.
RENOLIT is an enterprise with 75 years of development history and 20 years of production experience in Beijing
With the vigorous development of China's biological market, the group decided to realize localized production in the Beijing plant.
The strategic cooperation agreement reached with Lechun Biotechnology is not only to help China's outstanding biotechnology companies, but also to the Renault Group for China and the Asia-Pacific.
A commitment to the stable supply of the regional market in the future
.
Qin Sunxing, founder and chairman of Lechun Biotech, said: This year is an unusual year for all antibody and vaccine manufacturers
.
As a supply chain enterprise in the production of antibodies and vaccines, Lechun Biotechnology has been under tremendous pressure
Despite the shortage of supply chain this year, RENOLIT is still able to promote the pace of localized production in China and guarantee customer supply
.
Thanks to Renault for its support.
Lechun Biotech CEO Wang Feng, Lechun Biological Sales Vice President Zhu Linhua, Renault Medical Health-Beijing Business Unit Executive Deputy General Manager Jiang Xin, Renault Medical Health-Beijing Business Unit Sales Manager Sun Zhiyang as witnesses witnessed this Historical moment
.
Lechun Biotechnology was established in 2011.
As a leader in domestic disposable biotechnology solutions, it specializes in R&D and production of disposable biopharmaceutical process equipment and consumables, localizes disposable process technology, and promotes the continuous progress of China's biotechnology , As of December 2020, more than 500 biopharmaceutical companies in China use Lechun Biologics products
.
RENOLIT was established in 1946 as a developer of medical plastic resins and rubber products
.
As one of the industry's leading suppliers of packaging materials for many key applications, it has focused on the field of infusion and pharmaceutical packaging materials for more than 20 years
